IBP-9414

About Infant Bacterial Therapeutics

Infant Bacterial Therapeutics is a clinical-stage biotech focused on pioneering Live Biotherapeutic Products (LBPs) for premature infants. The company's lead asset, IBP-9414, is in late-stage development and aims to prevent necrotizing enterocolitis (NEC) and improve feeding tolerance. IBT has a broader pipeline targeting other infant diseases and antibiotic-resistant infections. As a public company based in Stockholm, it is positioned at the intersection of the microbiome and neonatal care markets.

About Infant Bacterial Therapeutics AB

IBT's mission is to pioneer live biotherapeutic products to prevent and treat life-threatening conditions in premature infants, a population with significant unmet medical needs. The company's core achievement is advancing its lead candidate, IBP-9414 (Lactobacillus reuteri), into late-stage development for necrotizing enterocolitis (NEC) and feeding intolerance, positioning it to potentially launch the first drug in this novel therapeutic class. Its strategy is intensely focused on neonatal care, with a pipeline built upon a proprietary platform of bacterial strains sourced from human breast milk and infant gut flora. With a public listing on Nasdaq Stockholm and a valuation near $660 million, IBT is a specialized pure-play in the emerging field of neonatal microbiome therapeutics.

Therapeutic Areas